FDA approvals are less influential on prescribing patterns than pharmaceutical sales marketers are, according to a study in Health Affairs. University of California and Harvard researchers examined the prescribing of antidepressants and antipsychotics by pediatricians and child and adolescent psychiatrists at thirty-one academic medical centers in five US states between 2006 and 2009. When the centers restricted visits by pharmaceutical sales representatives, prescriptions for both on-label and off-label uses of drugs that the reps typically were promoting dropped significantly. Conversely, use of non-promoted drugs in both categories increased. “Our results suggest that in these classes of drugs, detailing influences physician prescribing more than FDA approval does,” wrote the researchers.
Restrictions On Pharmaceutical Detailing Reduced Off-Label Prescribing Of Antidepressants And Antipsychotics In Children (Larkin, I et al. Health Affairs, 33, no.6 (2014):1014-1023 doi: 10.1377/hlthaff.2013.0939)